We are pleased to announce that DGT has has been recognised as the top recruiting site for January 2026, with 5 new recruits for the IP9 – ATLAS trial.
The Approaches To Long‑Term Active Surveillance (ATLAS) trial is a study designed to improve how men with low‑risk prostate cancer are monitored over time. Active surveillance means keeping a close watch on the cancer rather than starting treatment straightaway. This approach helps many men avoid or delay treatments they may not need, while still making sure any changes in the cancer are picked up early.
In this study, researchers are comparing the current standard method of active surveillance with a newer approach:
- Current method: regular PSA blood tests and rectal examinations
- Newer method: regular MRI scans alongside PSA blood tests
MRI scans can give doctors a clearer picture of the prostate, but it’s not yet known whether this approach is better than the current method. That’s why a large study like ATLAS is needed.
By comparing these two ways of monitoring prostate cancer, the trial aims to find out which approach is more accurate, more reassuring for patients, and better at spotting any changes early. The results will help guide future care for men choosing active surveillance.
Well done to our Research team!